Successful Eloctaq bid should widen access to the drug in the UK

29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with ...

Read more →

HyQvia gets a higher price

8 May 2020 - HyQvia 100 mg/mL solution for injection contains human immunoglobulin, which is an antibody used to strengthen ...

Read more →

CSL Behring Australia commences development of treatment for serious cases of COVID-19

6 May 2020 - Plasma-derived therapeutic with potential to treat serious complications of COVID-19. ...

Read more →

COVID-19: potentially life saving immunoglobulin treatment for seriously ill Australians

6 May 2020 - The Australian Government welcomes the announcement by CSL Behring that Australia will be one of the first ...

Read more →

CSL ramps up development of COVID-19 plasma treatment

6 May 2020 - Australia’s biggest health company CSL has confirmed it will immediately begin development of plasma-derived therapy to ...

Read more →

Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with Ruconest

30 April 2020 - European Commission decision was received six weeks earlier than expected. ...

Read more →

CSL's blood payments in US under the microscope

25 April 2020 - CSL has been forced to defend the way it runs its blood plasma collection business in ...

Read more →

Andexanet alfa for reversing anticoagulation

21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa ...

Read more →

Cows come home for CSL in COVID-19 vaccine battle

8 April 2020 - It sounds like a pitch for a sci-fi thriller — using genetically modified cows to fight ...

Read more →

Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy

6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...

Read more →

FDA approves additional treatment for adults and adolescents with haemophilia A or B and inhibitors

1 April 2020 - The U.S. FDA today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding ...

Read more →

TLV is reviewing the subsidy of factor VIII drugs with side agreements

28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...

Read more →

Octapharma’s fibryga receives European label extension to treat acquired fibrinogen deficiency (AFD)

5 November 2019 - Octapharma announced today that the human fibrinogen concentrate fibryga has received approval for use in treatment of ...

Read more →

A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing

5 November 2019 - A severe shortage of immune globulin — a popular medicine used to treat epilepsy, cancer and ...

Read more →

FDA approves Octapharma’s Wilate for haemophilia A in adult and adolescent patients

8 October 2019 - Octapharma USA today announced the U.S. FDA has approved Wilate for treatment of adults and adolescents with ...

Read more →